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Identified 87 miRs differentially regulated in TB patients versus healthy controls  
5 miRNA signature has biomarker potential to identify active TB patients 
miRNA modified with successful anti-TB treatment, potential predictor of treatment success 
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Objective: microRNA expression profiles are of interest as a biomarker of tuberculosis (TB). 
How anti-TB therapy effects miRNA profiles is unknown and was examined. 
Methods: We identified 87 plasma miRNAs that were significantly modified in an 
exploratory group of 19 Chinese pulmonary TB (PTB) patients compared to 14 healthy 
controls. We selected 10 of these miRNAs for analysis in a cohort of 100 PTB patients prior 
to, and at one, two and six months during treatment.  
Results: Five miRNAs were differentially expressed in PTB patients compared to controls at 
diagnosis; miRs -29a and -99b were up-regulated, whilst miRs -21, -146a and -652 were 
down-regulated. A combination of 5 miRNA distinguished TB from healthy controls with a 
sensitivity of 94%, a specificity of 88%, and an AUC of 0.976. Within one month of 
treatment, significant changes in miRs -29a, -99b, -26a and 146a levels occurred in 
successfully treated patients, although not all miRNAs returned to baseline by treatment 
completion. 
Conclusion A 5-miRNA signature shows potential for development as a novel biomarker for 
TB disease with potential to predict response to treatment. The failure of all miRNA to return 
to baseline levels may reflect ongoing remodelling in the lung parenchyma that continues 


















Tuberculosis (TB) continues to be a major global health problem with over 10 million new 
cases of active TB and 1.8 million deaths from TB each year(1). The WHO has set the 
ambitious goal of reducing TB deaths by 95% and the incidence of new TB cases by 90% by 
2035 (2), but this will not be achieved without the development of new interventions, 
including new therapeutics to combat drug-resistant TB and shorten the length of therapy and 
a more effective vaccine. New biomarkers that could help identify individuals with active 
disease or predict the response to treatment would also aid efforts to control TB disease (3). 
Diagnosing active TB can be challenging. Sputum can be difficult to collect from children, 
the elderly and HIV co-infected patients. Facilities for sputum culture are often not available. 
Most commonly TB is diagnosed based on symptoms, and X-ray where available and WHO 
estimates that over 3 million individuals who develop TB every year go undiagnosed or 
unreported (4). Therefore, a simple and reliable biomarker that correlates with the presence of 
active TB would be useful to prevent delay in diagnosis. Furthermore, biomarkers that 
correlate with the response to anti-microbial therapy may allow early recognition of treatment 
failure and possible drug resistance and be used as surrogate endpoints in late phase drug and 
vaccine studies, by greatly reducing the prolonged follow-up period currently required (5, 6). 
 
microRNAs (miRNAs) show great promise as both diagnostic and prognostic biomarkers(7). 
miRNAs influence nearly all aspects of cell physiology, including cell proliferation, 
differentiation and apoptosis (8). Mycobacterium tuberculosis infection of macrophages 
modifies the expression of multiple miRNAs, although the functions of most of these 
miRNAs are currently unknown. Some, such as miR-155 and miR-146, have been 













infection, both in vivo and in vitro (9, 10). Studies have shown changes in blood miRNA 
levels in small numbers of patients with active TB that have biomarker potential (11-13). 
 
Patterns of expression of plasma miRNAs have proven to be reliable as a prognostic indicator 
for some malignancies and infectious diseases (14, 15). The current study has examined the 
potential of an miRNA expression profile in the plasma to serve as a biomarker in patients 
with active pulmonary TB and to predict the response to therapy. 
 
Methods 
Study area and participants 
This study was undertaken in Ningxia Hui Autonomous region (NHAR) in north-western 
China where Han make up the majority ethnic group and Hui (Chinese Muslims), ~30%, the 
largest minority group. Participants were enrolled from five districts within NHAR. This 
study was undertaken with the approval of the University of Sydney Ethics Review 
Committee (Protocol No 2012/1076) and the Ningxia Medical University Human Ethics 
Committee (approval date 6/6/2013) between August 2013 and June 2014 and followed for at 
least 6 months. Written informed consent was obtained prior to enrolment in the study. 
 
Recruitment of study subjects 
Patients were recruited through the TB Control Program, in Yinchuan, Ningxia, China and 
enrolled consecutively from each of the nominated enrolment centres and enrolled at the time 
of the diagnosis, prior to the commencement of anti-tuberculous therapy. Selection criteria 
included; age greater than 18; no previous history of treated or untreated TB; and, not known 













findings, and sputum smear microscopy and mycobacterial culture according to National 
guidelines. TB patients enrolled in the study who were smear and culture negative, were 
diagnosed based on typical clinical symptoms and characteristic features of active PTB on 
chest radiographs. The lack of M. tuberculosis culture is not unusual in high-burden countries 
and serves to highlight the urgent need for the development of new diagnostic tools. Chest 
radiographs and chest-computerised tomography (where available) were reviewed 
independently by both a radiologist and thoracic physician.  
 
TB patients received therapy according to national guidelines that follow WHO DOTS 
guidelines. Blood was collected at A, prior to the commencement of therapy; B, C and D, 
following one, two and six months of standard Category One regimen including two months 
of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide followed by four months Isoniazid 
and Rifampicin. Patients were deemed cured if after standard therapy they achieved sputum 
culture conversion and/or (in the case of sputum-smear negative/culture negative TB) 
radiological clearance or significant radiological improvement.  
TB participants were asked to peer-nominate control subjects of the same ethnic group. 
Healthy controls with no history of TB, and of a similar age, gender and ethnicity were 
screened via interview and chest radiography to ensure they did not have active TB disease. 
 
Procedures 
A venepuncture protocol was designed and strictly followed to avoid any potential factors that 
may affect miRNA levels. Ten mL of venous blood was drawn from the cubital fossa from 
each patient at each collection into EDTA (BD Biosciences) tube. Blood was processed 
within 2 hours of collection. Blood was separated by centrifugation at 800 g for 10 minutes at 













plasma to prevent disturbance of the cellular layer and stored at -80°C. Samples collected 
from China were transported below -60°C to Australia and stored at -80°C. Prior to RNA 
isolation, samples were examined for haemolysis using a haemolysis chart and samples with 
> 100 mg/dL of haemoglobin were discarded. 
 
RNA in 500 μl of plasma was extracted using miRCURY™ RNA Isolation Kit (Exiqon, 
Vedbaek, Denmark) as per the manufacturer’s instructions. RNA quality was assessed using 
miRCURY
TM
 QC PCR panels, as per the manufacturers instructions. This measured the 
efficiency of amplification of low expressed miRNA and consistency of cDNA synthesis, 
qPCR efficiency and level of haemolysis. Samples that failed this QC were excluded from 
further analysis. qPCR reactions were prepared using the miRCURY LNA
TM
 Universal RT 
miRNA PCR Assay (Exiqon). cDNA was amplified to incorporate SYBR Green qPCR using 
miRNA-specific forward and reverse primers containing locked nucleic acids (LNAs) (16). 
 
RNA for the exploratory study was loaded onto Plasma Focus miRNA PCR Panels (Exiqon) 
and the expression of 175 miRNAs examined as per the manufacturer’s instructions using a 
LightCycler®480 (Roche Life Sciences, NSW, Australia). RNA for the confirmation set was 
loaded onto custom-made qRT-PCR Panels (Exiqon) with the following miRNAs measured: 
miR-21-5p; -99b-5p; -29a-5p; -223-5p; -221-3p; -146a-5p; -26a-5p; -28-5p; -133a; and, -652-
3p referenced to miR-93 which we had previously established to be a reliable miRNA to 
normalise miRNA in plasma samples (17). The PCR reactions were initiated with 10 min 
incubation at 95°C followed by 45 cycles of 95°C for 10 sec and 60°C for 1 minute. Melting 

















Statistical analysis  
The relative expression of each target miRNA was calculated according to the difference in 
quantification cycle (Cq) values between the target miRNA and the reference miRNA miR-93 
using the 2
-ΔΔCT
. Groups were tested for normality by the Kolmogorov-Smirnov test and 
Student’s t-test and descriptive statistics, linear and logistic regression performed, and 
receiver operating characteristic (ROC) graphs generated with SPSS Predictive Analytic 
Software V.21 (IBM Corp, Chicago, Illinois) and GraphPad Prism 7 (San Diego, CA, USA).  
One-way analysis of variance (ANOVA) was used to determine significance of differences in 




Twenty patients with newly diagnosed PTB and an average age of 46 (range 18-69) were 
recruited and compared to 20 healthy controls (Table 1). Plasma miRNAs were extracted and 
examined with the Plasma Focus miRNA PCR panel.  QC analysis of the plasma, the miRNA 
and the miRNA plates excluded 7 samples from further analysis with 19 TB patients and 14 
healthy controls included in the final analysis. Among the 175 miRNAs analysed, 87 miRNAs 
were identified with significantly altered expression between PTB patients and healthy 
controls by qRT-PCR, with 69 down-regulated and 18 up-regulated in PTB patients 
(Supplementary Table 1 and 2). 
 
Ten miRNAs that were significantly differentially expressed were selected for analysis in the 
confirmatory group of 100 TB patients and control subjects (Figure 1 and Table 2). These 













values < 32, and published evidence of their regulation in TB infection or macrophage 
function.  
Confirmatory study 
A total of 100 treatment naïve patients with newly diagnosed PTB, were successfully 
followed for six months, together with matched healthy control subjects (Table 1). Eighty-
nine of the TB patients were successfully treated as defined by either sputum conversion 
(AFB smear negative and/or M. tuberculosis culture negative) and/or clinical and radiological 
resolution as determined independently by both a radiologist and a thoracic physician, with 
eleven classified as treatment failures.  At the commencement of therapy five of the ten 
miRNA measured were differentially expressed in the TB patients (Figure 2). miRs -21, -146a 
and -652 were significantly down-regulated in the TB patients, while miR-99b and miR-29a 
were significantly up-regulated (Table 2). 
 
To determine if any of the significantly regulated miRNAs, either alone or in combination, 
could successfully differentiate TB from healthy controls, receiver operator curves (ROC) 
were constructed (Supplementary Figure 1). These showed values for the area under the curve 
(AUC) of between 0.64 and 0.70 when individual miRNAs were used. A logistic regression 
analysis was performed to examine if combining miRNA expression levels improved the 
accuracy of assignment. A combination of all ten miRNAs yielded a sensitivity of 94.6% and 
specificity of 88.8% for the diagnosis of TB prior to therapy, with a positive predictive value 
(PPV) of 88% and a negative predictive value (NPV) of 95% (Figure 3, Table 3) and 
associated AUC of 0.978. Examining the effect of different combinations of the miRNA 
determined that a group of 5 miRNA (miRs -146a, -99b, -28, -221 and -29a) yielded a 
sensitivity of 94% and a specificity of 88% for the presence of active TB with an AUC of 













of a disease. Likelihood ratios, on the contrary, are independent of disease prevalence (18). 
The positive (PLR) and negative (NLR) likelihood ratio for active PTB were calculated for 
the miRNA panels, and this yielded a PLR of 5.29 and NLR of 0.12 for the five-miRNA 
signature and a PLR of 8.6 and 0.06 for the complete 10 miRNA signature.  
 
In many parts of China and indeed globally PTB is diagnosed when the sputum smear is 
negative and mycobacterial culture is not available. Of the patients enrolled in this study 33 
were confirmed by culture or sputum at diagnosis. miRNA expression was examined in this 
subset of patients and compared to their matched controls. The 10-miRNA panel actually 
gave a 100% specificity and sensitivity, successfully separated all 33 TB patients from their 
respective healthy controls. The 5-miRNA-panel similarly gave yielded a sensitivity of 97% 
and a specificity of 94% with an AUC of 0.984 for active PTB, indicating a strong correlation 
with this smaller subset of culture confirmed TB patients. 
 
TB patients and healthy controls were further stratified based on ethnicity, age and gender. 
There were no significant differences in miRNA levels based on gender or age (stratified as 
under 40 and over 40 years) between the groups (Supplementary Figure 2). The individuals 
recruited to this study self-identified as either Han Chinese or Hui Chinese. Analysis of 
plasma miRNA levels showed a difference in miR-29a expression between PTB patients from 
these two groups (Supplementary Figure 2), however a larger sample size would be required 
to validate this finding. 
 
The effect of anti-tuberculous treatment on the miRNA plasma profiles of the TB patients 
were measured after one, two and six months of standard anti-TB therapy. After one month, 













compared to the levels at the commencement of therapy (Figure 4), however only miR-99b 
and miR-29a returned to levels equivalent to the healthy controls by the completion of 
therapy (Figure 4). Of the 100 TB patients in the cohort, 89 were classified as cured at the 
completion of therapy. Interestingly miRNA levels in the 11 individuals who were classified 
as treatment failures showed a trend to be more differentially expressed as compared to the 
healthy controls than the plasma miRNA levels in the patients who successfully completed 
treatment at the time of diagnosis (Figure 5). The miRNA levels in the treatment failures did 
not change significantly during the first month of therapy, but approached the levels seen in 
the treatment success by the completion of therapy (data not shown). However, these data are 
from a small sample of only 11 treatment failures, and further study of a larger sample size is 
required to confirm this finding. 
 
Discussion 
The exploratory study demonstrated that M. tuberculosis disease resulted in significant 
changes in the levels of 47% plasma miRNAs examined demonstrating that miRNA 
expression is significantly modulated during active TB. The levels of 10 of these miRNA 
were then examined in a longitudinal confirmatory study of 100 PTB patients sampled at four 
time points during therapy. Of the ten selected miRNAs that were differentially expressed in 
the exploratory study, only six were significantly modulated in the larger cohort study, 
highlighting one of the potential risks of variation in miRNA levels in relatively small sample 
sizes. This variation may also be due to differences in baseline miRNA expression. Our 
understanding of baseline miRNA expression across populations is limited. In this study 
stratifying for age or gender did not show any significant differences in the control or TB 
groups, however some differences in miRNA levels were noted between the Han Chinese and 













differences in baseline miRNA levels. Whether these differences are due to genetic 
differences or factors such as environment, diet, lifestyle or other co-morbidities requires 
further examination in larger cohorts.  
 
Our understanding of how M. tuberculosis infection modulates miRNA expression and the 
most appropriate miRNA to include in a biomarker panel also requires further research. We 
selected 10 miRNA from 87 that were differentially regulated in our study, with only six 
reaching significance in our confirmatory study. Other recent biomarker studies have 
identified additional miRNA that may have biomarker potential to aid TB diagnosis. miRs-
144, -223, -29a, -155 and 424 have all been reported as providing AUC over 0.8 or sensitivity 
and specificity over 80% as a single miRNA biomarker aiding TB diagnosis (12, 22-25).  Of 
these, only miRs -223 and -29a were significantly regulated in our exploratory study, with 
only miR-29a remaining significantly regulated in the validation study. These differences 
may reflect differences in ethnicity, latent TB status, and environmental or other risk factors, 
such as diabetes or smoking which were not evaluated in this study, but should be examined 
in larger future studies. 
 
Using a miRNA panel over a single miRNA is one option to increase the sensitivity and 
specificity of the biomarker. This study found a five-miRNA combination demonstrated a 
maximum sensitivity of 94% without compromising specificity, at 88%, for the presence of 
active PTB in a Chinese cohort. A study by Miotto et al. (21) on TB patients from Italy, 
Uganda and Tanzania, identified a 15 miRNA panel that differentiated HC from PTB with an 
AUC of 0.9528.  Seven of these miRs were also down regulated in our study, although 
another seven were not differentially expressed in our exploratory study. Larger studies, 













time points are required to confirm the most promising miRNAs with diagnostic potential for 
TB. 
 
Another finding from this longitudinal study was the significant changes in miRNA 
expression over the course of therapy. Initially it was hypothesised that a positive response to 
anti-tuberculous therapy would be reflected by changes in the miRNA profiles back to the 
levels present in healthy controls. This was the case for only two of the miRNA examined, 
including miR-99b that returned to levels equivalent to healthy controls within a month of 
starting anti-tuberculosis chemotherapy and miR-29a where this took six months. In the 89 
TB patients classified as treatment successes, a significant change in miRs -99a, -29 and -26a 
occurred within a month of commencing treatment, suggesting that changes in miRNA levels 
may be utilised as a measure of treatment response.  
 
Some miRNAs had not returned to the levels in healthy controls by the end of the treatment 
period. The reasons for this require further investigation. Possibly the persistent down-
regulation of miR-146a may be a protective measure to control for the deleterious effects of 
an unregulated inflammatory response, and this may counteract the pro-inflammatory effects 
thought to be associated with down-regulation of miR-21a (26) and miR-26a (27, 28). The 
miRNAs may remain down-regulated because of continuing lung inflammation and 
parenchymal re-modelling that accompanies resolving pneumonic infection. It is important to 
note that the cause of the observed changes in plasma miRNAs or the target sites for these 
miRNAs are not known. Recently, serial PET scanning of the lungs during treatment for PTB 
revealed that at the completion of therapy, only 14% of patients had fully resolved lesions, 
51% of patients had increased metabolic activity in the original lung lesions, and in 18% of 













inflammatory changes persist despite microbiological improvement, and this inflammation 
may contribute to persistent changes in some plasma miRNA levels. Other factors may also 
have an impact on plasma miRNA expression, such as the duration of active TB prior to 
therapy, intercurrent illness, diet and smoking history, and these should be addressed in a 
larger cohort of patients to determine whether miRNA expression patterns could be used 
successfully as a predictor of treatment outcome.  
 
This study demonstrates that miRNA levels in PTB patients differ from health controls. One 
limitation of this study is that we did not compare the sensitivity or specificity of our 
biomarker panel to distinguish PTB from other respiratory diseases, such as bacterial 
pneumonia. This may produce similar radiological changes, particularly in the context of 
immune-compromised individuals (30). A serum seven-protein biosignature was able to 
distinguish active PTB from other chest infections and acted as a triage tool in the diagnosis 
of PTB in a primary care setting (31). Second, the control population in the current study 
were screened to exclude active TB by symptoms and chest radiography, but not for latent TB 
infection (LTBI). As TB is endemic in China with an estimated case detection rate of 423 per 
100,000 in western China (32) it is likely that many of the healthy controls have LTBI. Both 
transcriptional and protein biomarkers that distinguish subjects with active TB from health 
controls are also negative in the vast majority of subjects with LTBI (31, 33), however future 
studies should determine if miRNA expression is affected by LTBI. Finally. miRNA levels 
were measured in the healthy control subjects once at only one time point. It would be 
informative to test the control subjects at multiple times to determine if plasma miRNA 
expression fluctuates in healthy individuals. Nevertheless, the five-miRNA signature clearly 
identified subjects with active TB with a sufficient PLR of 5.29 and NLR of 0.12 to suggest it 














Recent studies have shown that suppression of a single miRNA can partially regulate M. 
tuberculosis survival (34, 35). Further translational research to enhance our understanding of 
miRNAs as a diagnostic and prognostic tool as well as a target for host-directed therapy has 
the potential to improve the management of patients with TB disease. 
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Table 1. Characteristics of the TB patients and controls for exploratory and 

































Total Number 19 100 14 100 
Gender (male/female) 10/9 58/42 8/6 57/43 









Ethnicity  Han 1 42 1 46 
Hui 18 58 13 54 
Sputum Smear Positive 5 33  
Sputum Culture Positive 5 10  
Culture DST 2 10  
Chest X-ray with active 
TB  
19 100 













Table 2. Expression levels of 10 candidate plasma miRNAs in TB patients from the 
exploratory and confirmation sets from prior to the commencement of therapy. 
 Exploratory Set Confirmation Set 
miRNA Fold Change p –Value* Fold Change p –Value* 
miR-21-5p -2.28 <0.001 -1.83 0.005 
miR-99b-5p 2.54 <0.001 1.52 0.002 
miR-29a-5p 2.79 0.006 4.09 <0.001 
miR-223-5p 2.09 0.002 -1.01 0.767 
miR-221-3p 2.56 0.003 1.47 0.176 
miR-146a-5p -2.29 0.002 -2.66 <0.001 
miR-26a-5p -2.10 0.001 -1.26 0.192 
miR-28-5p 2.93 <0.001 1.72 0.105 
miR-133a -2.94 0.002 -1.08 0.305 
miR-652-3p -1.73 0.020 -1.37 <0.001 
 
miRNA levels for the exploratory set were measured by Plasma Focus miRNA PCR Panels  
(Exiqon), and for the confirmatory set by qRT-PCR, and all data normalised to levels of miR-  























Table 3. Logistic regression analyses of the combination of ten plasma miRNAs for the 
diagnosis of pulmonary TB in confirmation set. 
Variable Coefficient Std error p-value Odds Ratio 95% CI 
miR-21 0.996 0.774 0.198 2.708 0.594-12.356 
miR-26a -1.212 0.662 0.067 0.297 0.081-1.088 
miR-28 0.834 0.306 0.006 2.303 1.264-4.197 
miR-29a 1.011 0.283 <0.001 2.748 1.578-4.784 
miR-99b 2.019 0.6 0.001 7.53 2.322-24.416 
miR-133a -0.313 0.209 0.134 0.732 0.0486-1.101 
miR-146a -3.787 0.834 <0.001 0.023 0.004-0.116 
miR-221 2.092 0.544 <0.001 8.098 2.79-23.501 
miR-223 0.349 0.303 0.249 1.418 0.783-2.568 
miR-652 -1.003 0.709 0.157 0.367 0.091-1.471 




















Figure 1. Plasma levels of miRNAs in exploratory set of 19 TB patients and 14 healthy 
controls. Expression levels of 10 miRNAs in the plasma of 19 TB patients prior to 
commencement of treatment and 14 healthy controls were measured by qRT-PCR. The 
relative expression of the miRNA as defined by 2
-ΔCt
, was normalised against miR-93. Results 
shown are the median and 95% central range. Outliers are plotted individually. The statistical 
significance of the difference between the groups for each miR was determined by Student’s 
t-test. *p <0.05, **p <0.01, ***p <0.001. 
 
Figure 2. Plasma levels of miRNAs in confirmation set of 100 treatment naïve TB 
patients prior to therapy and 100 healthy controls. Expression levels of 10 miRNAs from 
100 TB patients prior to commencement of treatment and 100 healthy controls were measured 
by qRT-PCR. The relative expression of the miRNA as defined by 2
-ΔCt
, was normalised 






















































































































































































The statistical significance of the difference between the groups for each miR was determined 
by Student’s t-test. *p <0.05, **p <0.01, ***p <0.001. 
 
Figure 3. Increasing sensitivity and specificity of the miRNA panel to distinguish newly 
diagnosed TB patients from healthy controls. 
The specificity and sensitivity and area under the curve for combinations of 1 to 10 miRNA 
measured in 100 TB patients prior to commencement of treatment compared to 100 healthy 
controls were generated in SPSS V.21.  
 
Figure 4. Plasma levels of miRNAs in confirmation set of 100 TB patients and their 
matched healthy controls at all collection time points. Plasma from TB subjects was 
collected prior to the commencement of therapy (0 months) and after one, two and six months 
of therapy. miRNAs levels were examined by qRT-PCR. The relative expression of the 
miRNA as defined by 2
-ΔΔCt
, was normalised against miR-93.  Results are mean + 95% 
confidence intervals. The statistical significance of the difference between the groups and 














































































































































between time points for each miR was determined using ANOVA.*p <0.05, **p <0.01, ***p 
<0.001. 
 
Figure 5. Plasma levels of miRNAs in patients who were classified as treatment failures 
compared with healthy controls and treatment successes. Plasma from TB subjects was 





































































































was stratified based on treatment success (n=89, treatment failure n=11). Results are median + 
95% confidence intervals. The statistical significance of the difference between the groups 
and between time points for each miRNA was determined using ANOVA. *p <0.05, **p 
<0.01, ***p <0.001. 
 
